• Viking Therapeutics Inc VKTX.OQ reported a quarterly adjusted loss of 58 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -20 cents. The mean expectation of nineteen analysts for the quarter was for a loss of 45 cents per share. Wall Street expected results to range from -55 cents to -30 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Viking Therapeutics Inc's reported EPS for the quarter was a loss of 58 cents​.

• The company reported a quarterly loss of $65.56 million.

• Viking Therapeutics Inc shares had risen by 21.1% this quarter and lost 20.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 5.4% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Viking Therapeutics Inc is $101.00, about 68.2% above its last closing price of $32.10

This summary was machine generated from LSEG data July 23 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)